| Project/Area Number |
23590660
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Laboratory medicine
|
|---|
| Research Institution | Gunma University |
|---|
Principal Investigator |
HANDA HIROSHI 群馬大学, 医学部附属病院, 講師 (90282409)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MURAKAMI Hirokazu 群馬大学, 大学院保健学研究科, 教授 (40166260)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | iPS細胞 / 骨髄異形成症候群 / 細胞外マトリックス / 長期培養 / 疾患特異的iPS細胞 |
|---|
| Research Abstract |
Myelodysplastic syndrome (MDS) is the disease characterized by peripheral blood cytopenia, morphological abnormality of hematopoietic cells and chromosomal abnormality. MDS is also a lethal disease having two sides; bone marrow failure and pre-leukemia. In order to develop in vitro model system for MDS, we performed basic study to develop long term culture system of the disease specific iPS cell using cell free with extra-cellular matrix. Bone marrow specimens obtained from MDS patients after informed consent were separated and CD34 positive hematopoietic progenitor fraction was purified. Five transcription factors; OCT-4, SOX-2, KLF-4, LIN28, NANOG, were transfected to the purified hematopoietic progenitor cells to produce MDS-iPS, however we failed to maintain, grow and differentiate this iPS cells.
|
